NO20081379L - Pankreatinmikropelletkjerner egnet for enterisk belegning - Google Patents

Pankreatinmikropelletkjerner egnet for enterisk belegning

Info

Publication number
NO20081379L
NO20081379L NO20081379A NO20081379A NO20081379L NO 20081379 L NO20081379 L NO 20081379L NO 20081379 A NO20081379 A NO 20081379A NO 20081379 A NO20081379 A NO 20081379A NO 20081379 L NO20081379 L NO 20081379L
Authority
NO
Norway
Prior art keywords
pancreatin
enteric coating
pancreatin micropellet
cores suitable
micropellet cores
Prior art date
Application number
NO20081379A
Other languages
English (en)
Norwegian (no)
Inventor
Claus-Juergen Koelln
George Shlieout
Frithjof Sczesny
Jens Onken
Guido Ruesing
Original Assignee
Abbott Lab Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081379(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab Gmbh filed Critical Abbott Lab Gmbh
Publication of NO20081379L publication Critical patent/NO20081379L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20081379A 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning NO20081379L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70852605P 2005-08-15 2005-08-15
EP05107474 2005-08-15
PCT/EP2006/065313 WO2007020260A2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Publications (1)

Publication Number Publication Date
NO20081379L true NO20081379L (no) 2008-05-14

Family

ID=37401623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081379A NO20081379L (no) 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning

Country Status (15)

Country Link
EP (1) EP1931317B1 (cg-RX-API-DMAC7.html)
JP (1) JP5284092B2 (cg-RX-API-DMAC7.html)
KR (1) KR101302841B1 (cg-RX-API-DMAC7.html)
AT (1) ATE418329T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006281415B2 (cg-RX-API-DMAC7.html)
CA (1) CA2619477C (cg-RX-API-DMAC7.html)
DE (1) DE602006004471D1 (cg-RX-API-DMAC7.html)
ES (1) ES2320174T3 (cg-RX-API-DMAC7.html)
IL (1) IL189457A (cg-RX-API-DMAC7.html)
MX (1) MX2008001557A (cg-RX-API-DMAC7.html)
NO (1) NO20081379L (cg-RX-API-DMAC7.html)
PL (1) PL1931317T3 (cg-RX-API-DMAC7.html)
PT (1) PT1931317E (cg-RX-API-DMAC7.html)
RU (1) RU2408364C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007020260A2 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
RU2381813C2 (ru) 2004-03-22 2010-02-20 Зольвай Фармасьютиклз Гмбх Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав
CA2616943C (en) 2005-07-29 2016-04-12 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
CN101686943B (zh) 2007-02-20 2014-03-26 阿普塔利斯制药有限公司 稳定的消化酶组合物
CA2711187A1 (en) * 2008-01-03 2009-07-09 George Shlieout Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
GB2480773B (en) 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
CA3050530A1 (en) 2009-01-06 2010-07-15 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
EP2818160B1 (en) 2010-10-01 2017-11-08 Aptalis Pharma Limited Enteric coated, low-strength pancrelipase formulations
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
PL2489349T3 (pl) 2011-02-17 2014-09-30 Nordmark Arzneimittel Gmbh & Co Kg Granulki pankreatynowe, zwłaszcza mikrogranulki pankreatynowe, oraz sposób ich produkcji
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
KR101953413B1 (ko) 2011-08-08 2019-02-28 앨러간 파마슈티컬스 인터내셔널 리미티드 소화효소들을 함유하는 고형 조성물들의 용해 시험 방법
US10350278B2 (en) * 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
ES2784227T3 (es) 2013-08-09 2020-09-23 Allergan Pharmaceuticals Int Ltd Composición de enzimas digestivos adecuada para la administración entérica
WO2015193730A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
US20160120964A1 (en) 2014-11-05 2016-05-05 George Shlieout Processes for producing compositions with improved safety profile having lipase activity and compositions suitable for pharmaceutical use
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
EP3609528A4 (en) 2017-04-10 2020-12-23 Curemark, LLC COMPOSITIONS FOR THE TREATMENT OF ADDICTION
RU2706003C1 (ru) * 2019-09-09 2019-11-13 Акционерное общество "АВВА РУС" Микрогранулы, содержащие панкреатин
MD4900C1 (ro) * 2020-06-10 2025-03-31 Kusum Healthcare Private Limited Compoziţie farmaceutică de pancreatină şi procedeu de preparare a acesteia
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR20250116893A (ko) 2024-01-26 2025-08-04 황준영 판크레아틴 함유 속방성 장용코팅 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
ES2194720T3 (es) * 1999-03-17 2003-12-01 Solvay Pharm Gmbh Enzimas para el tratamiento de diabetes mellitus tipo i.
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
ES2320174T3 (es) 2009-05-19
CA2619477C (en) 2015-05-26
RU2008109651A (ru) 2009-09-27
KR101302841B1 (ko) 2013-09-02
JP2009504710A (ja) 2009-02-05
PT1931317E (pt) 2009-02-02
RU2408364C2 (ru) 2011-01-10
EP1931317A2 (en) 2008-06-18
WO2007020260A2 (en) 2007-02-22
EP1931317B1 (en) 2008-12-24
IL189457A0 (en) 2008-06-05
IL189457A (en) 2014-05-28
AU2006281415B2 (en) 2012-01-19
PL1931317T3 (pl) 2009-06-30
ATE418329T1 (de) 2009-01-15
HK1119559A1 (en) 2009-03-13
AU2006281415A1 (en) 2007-02-22
CA2619477A1 (en) 2007-02-22
MX2008001557A (es) 2008-02-15
KR20080034516A (ko) 2008-04-21
WO2007020260A3 (en) 2007-05-10
JP5284092B2 (ja) 2013-09-11
DE602006004471D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
NO20081379L (no) Pankreatinmikropelletkjerner egnet for enterisk belegning
NI201200072A (es) Métodos y composiciones para tratar cáncer
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
WO2011044089A3 (en) Methods of treating depression and other related diseases
WO2016061464A8 (en) In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
NO20090968L (no) Fremgangsmater for a behandle multippel myeloma ved anvendelse av kombinasjonsterapier basert pa anti-CS1 antistoffer
WO2008098184A3 (en) Methods for the induction of a cell to enter the islet 1+ lineage and a method for the expansion thereof
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
EP2331562A4 (en) PEPTIDES WITH AN EPITOPE OF A DOMAIN OF THE FACTOR H-BINDING PROTEIN AND METHOD OF USE
MX2010008789A (es) Proceso para reducir el daño del cabello despues del tratamiento del cabello con calor.
WO2011156602A3 (en) Method, system, and composition for coloring zirconia dental ceramics
IL161903A0 (en) Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
TW200602089A (en) Sugar coatings and methods therefor
MX2009010534A (es) Tecnologia de plataforma farmaceutica para el desarollo de productos naturales.
EP1832275A3 (en) Hair styling compositions containing a silicone elastomer and a non-aqueous polar solvent
EP2264048A4 (en) PEPTID DES [ASP1] - [ALA1] -ANGIOTENSIN (1-7) -AGONIST AND PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF DISEASES
EP3914264A4 (en) OLIGODENDROCYTE PROGENITOR CELLS DERIVED FROM THE BACK FROM HUMAN PLURIPOTENT STEM CELLS
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
CL2012003028A1 (es) Tableta entérica que comprende: 1) 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina o sus sales y 2) una capa de recubrimiento entérico que comprende a) uno o mas componentes poliméricos como copolímero de ácido metacrílico, b) talco y c) sin componente alcalino, útil en el tratamiento de trastornos del humor como depresión o ansiedad.
DK2151235T3 (da) Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
EP1970099A3 (en) Process for relaxing or straightening hair
EP3735587A4 (en) SYNCHRONIZED CELL CYCLE GENE EXPRESSION TEST FOR ALZHEIMER'S DISEASE AND RELATED THERAPEUTIC PROCEDURES
MA28563B1 (fr) 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation
UA89102C2 (ru) Ядра микропеллета панреатита, пригодные для нанесеня энтеросолюбильного покрытия
WO2011076946A3 (en) Methods and compositions for the treatment of alzheimer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT LABORATORIES GMBH, DE